RE: "Conjugated equine estrogens and breast cancer risk in the women's health initiative clinical trial and observational study"

American Journal of Epidemiology

Volumn 168, Issue 10, 2008, Pages 1213-

  Shapiro, Samuel ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE;

BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CLINICAL TRIAL; HUMAN; LETTER; OBSERVATIONAL STUDY; WOMEN'S HEALTH; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; NOTE; RISK ASSESSMENT;

EQUIDAE;

BREAST NEOPLASMS; CONTRACEPTIVE AGENTS, FEMALE; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; RISK ASSESSMENT;

EID: 56149113833     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn316     Document Type: Letter

References (3)

1. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol. 2008;167(12):1407-1415.
2. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647-1657.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.